2025 AACR Annual Meeting Posts
CD38 plays critical role in multiple myeloma progression
A mouse model confirmed the aggressive nature of CD38 expression in multiple myeloma (MM), which induces widespread metastasis, extensive bone degradation, renal involvement, and heightened immunosuppression.
Off-the-shelf CAR NK-cell therapy shows promise for relapsed or refractory AML
A study presented at the American Association for Cancer Research Annual Meeting 2025 found that the investigational chimeric antigen receptor (CAR) therapy SENTI-202 induced complete remission in patients with relapsed or refractory acute myeloid leukemia (AML).
Trispecific therapy ISB 2001 active in ongoing early myeloma trial
ISB 2001, a trispecific T-cell engager targeting BCMA and CD38, showed expected immune activity and no dose-limiting toxicities in an ongoing phase 1 study in relapsed or refractory multiple myeloma […]
RNA-seq maps genetic, nongenetic drivers of AML
Investigators used RNA sequencing to create a new gene activity atlas that showed how normal blood cells developed. The technique also identified the different ways abnormal development can lead to […]
AACR honors Larry Saltzman with 2025 Distinguished Public Service Award
The American Association for Cancer Research (AACR) has named Larry Saltzman, MD, a recipient of the 2025 Distinguished Public Service Award for his advocacy to secure National Institutes of Health […]
